Medical World News® Deep Dive: Making Cell and Gene Therapy Practical

Video

Josh Ludwig detailed to CancerNetwork® how ScaleReady can help make cell and gene therapy widely practical and viable for patients with cancer.

In a recent episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Josh Ludwig, the global director of commercial operations at ScaleReady, about how a joint venture launched in January 2021 between Bio-Techne, Fresenius Kabi, and Wilson Wolf is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.

Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Related Content
New Cohort Approved in Phase 1/2 Trial of TTX-MC138 in Solid Cancers

New Cohort Approved in Phase 1/2 Trial of TTX-MC138 in Solid Cancers

Tim Cortese
March 13th 2025
Article

Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.

Considerations for Equity and Regulations for AI Tools in Oncology

Roman Fabbricatore
March 12th 2025
Article

Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

nenetus-stock.adobe.com

Celebrating Women in Oncology Through Their Impactful Research and Insights

Ariana Pelosci
March 7th 2025
Article

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

Denosumab Biosimilars Approved by FDA for Previously Referenced Indications

Denosumab Biosimilars Approved by FDA for Previously Referenced Indications

Tim Cortese
March 5th 2025
Article

The FDA has approved 2 denosumab biosimilars for all prior approvals for the reference drugs in patients with cancers and osteoporosis.